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PRM71
ReiMbuRseMent Decisions in oncology DRugs: An inteRnAtionAl 
AnAlysis
Aissaoui A
Paris dauphine University, Paris, France
Objectives: The aim is to compare the drug reimbursement decisions of innova-
tive anti-cancer drugs in five countries (UK, France, Italy, Spain & Australia). Our 
approach was to identify both convergence and divergence in these reimbursement 
decisions and to assess the agreement level between the policy makers. MethOds: 
For our analysis we have used 39 oncology drugs authorized by the EMA between 
January 2004 and December 2012 covering a total of 65 indications, and we have 
compared the reimbursement decisions in theses 5 countries. We reviewed the 
technology appraisal performed by their respective national HTA agencies and their 
reimbursement decisions. We have also analyzed the level of agreement for reim-
bursement decisions between pairs of each country with kappa scores. Results: 
Out of these 39 drugs, only 16 drugs were reimbursed in Australia, 15 in England, 
38 in France, followed by Italy and Spain, which respectively reimbursed 29 and 28 
drugs. When we have analyzed the common reimbursement decision taken, we 
have observed that between France and Italy 72% of common positive reimburse-
ment decision were taken, and between France and England only 33 % of positive 
reimbursement decisions are common. In contrast we have found 49 % of common 
negative reimbursement decision between England and Australia. Then we have 
measured the consistency between decision makers with KAPPA scores and it came 
out that France, Italy and Spain are often in agreement in their reimbursement deci-
sions, and that conversely France and England decisions are significantly in disa-
greement. cOnclusiOns: This study demonstrates that the discordance between 
countries reimbursement decisions, in most cases may reflect the differences in 
the decision making process (Eg. France Vs England). But this analysis cannot be 
conclusive. This is why we have carried out further researches using larger datasets 
allowing us to highlight some elements yielding to these reimbursement decision 
differences between countries.
PRM72
eAsy coMe, HARDly go: ePiDeMiologicAl MetHoDs to evAluAte tHe 
effect of isPoR boARD of DiRectoRs MeMbeRsHiP on PublicAtion 
Activity
Merész G.1, Gyurcsán G.C.2, Salfer B.3
1Syreon Research Institute, Budapest, Hungary, 2Self-employed, Budapest, Hungary, 3Healthware 
Consulting Ltd., Budapest, Hungary
Objectives: ISPOR is approaching its 10th anniversary, which offers a suitable occa-
sion to assess the impact of the organization. As the number of members increased, 
the influence of the Board of Directors on scientific discussions also emerged. The 
aim of this research is to present what effect being elected an ISPOR Director has 
on a researcher’s publication activity by using epidemiological methods and data 
mining techniques. MethOds: Data on number of publications by year, co-authors, 
titles, abstracts of former ISPOR Directors between 1995 and 2012 were obtained 
from public sources (ISPOR website and PubMed) and analysed by an algorithm 
developed by the authors in R. A case-only study design was applied by matching the 
duration spent as a member of the Board of Directors with the same period prior to 
and after finishing the directorate term. Incidence rate ratios (IRR) were estimated 
by fitting separate Poisson regression models to correct for the baseline increase 
in publication activity. The average number of co-authors and probability of the 
director being the first author was also analysed. Results: The IRR of the period 
preceding to directorate versus the directorate period was 1.59 (CI 95%: 1.34-1.91), 
yielding statistically significant association. The IRR of directorate period versus the 
period succeeding the directorate period was 1.01 (CI 95%: 0.88-1.13). The average 
number of co-authors was the highest after the directorate term (5.94); the probabil-
ity of the director appearing as the first author was the highest prior to directorate 
term (22.91%). cOnclusiOns: As a result of our study, it has been statistically 
proven that being an ISPOR Director does not only provide leadership in a scientific 
organization, but can enhance the members’ career as a researcher. ISPOR Directors 
are more likely to co-author publications even after finishing their directorate term.
ReseARcH on MetHoDs – Modeling Methods
PRM73
cReAting PAtient PRofile in inDiviDuAl siMulAtions: A coMPARison of 
APPRoAcHes
Stern S., Pan F
Evidera, Bethesda, MD, USA
Objectives: Individual simulation is increasingly used in economic models, partly 
because of its capability of predicting event risks based on individual patient char-
acteristics. However, due to lack of individual patient level data, models often use 
means and standard deviations to create patient profiles. The objective of this study 
is to evaluate different simulation approaches of creating patient profile at baseline 
and their impact on model outcomes. MethOds: Patient level data (N= 8,857) from 
National Health and Nutrition Examination Survey (NHANES) was used to evalu-
ate three approaches of creating baseline patient profiles for simulation models. 
10 samples of 1000 patients each were created through 1) random sampling from 
patient level data; 2) using means and standard deviations of the profile variables 
without correlating the characteristics; 3) using means and variance-covariance 
matrix among the continuous variable characteristics with cholesky decomposi-
tion approach. 10-year cardiovascular diseases (CVDs) rates are estimated using the 
created patient profiles from these 3 different approaches. Results: The predicted 
CVD rates based on random sampling are 18.2% for males and 9.7% for females using 
the random sampling approach, 14.5% for males and 7.9% for females using the 
mean and standard deviation approach and 16.0% for males and 9.2% for females 
using the cholesky decomposition approach. The CVD rates using the NHANES entire 
positive association (p< 0.05) with different cardiovascular outcomes. However, in 
the multivariate models, only those experiencing heartburn (adjusted OR 1.3, 95% 
CI 1.0-1.7) during pregnancy were at greater risk of having hypertension 21 years 
post partum. Women experiencing morning sickness (adjusted OR 1.2, 95% CI 0.8-
2.0) and backache (adjusted OR 1.1, 95% CI 0.6-1.7) were not considered to be at 
risk for future heart disease. cOnclusiOns: As a whole, our study suggests that 
most common symptoms of pregnancy are not associated with an increased risk 
of cardiovascular disease or with hypertension in the long term.
PRM68
incReAseD AccuRAcy of DistRibution bAseD Missing vAlue iMPutAtion: 
An AlteRnAtive to MeAn inPutAtion in ReAl WoRlD enviRonMent 
suRvey ReseARcH
Wasser T., Eisenberg D.
HealthCore, Inc., Wilmington, DE, USA
Objectives: Missing values within variables can impede accurate data analysis 
on many levels including both univariate and multivariate analysis. This research 
presents distribution-based imputation (DBI), where the distribution of non-missing 
values is simulated to create a set of values that are then randomly inserted into to 
the missing values in the actual data and compares this against mean based imputa-
tion (MBI). MethOds: DBI was compared to MBI in 12 different simulation condi-
tions based on three sample sizes (50, 100, 150 and 200) and three different missing 
value percentages for each of the sample sizes (10%, 20% and 30%). Each simulation 
created 1,000 test datasets within each condition for a total of 12,000 simulated 
datasets. The statistical package, R was used for the sumilation. Results: MBI 
was biased by simulating smaller Standard Deviations, and less accurate in mean 
estimation than DBI in all 12 simulation combinations. DBI was more accurate in 
matching the number of rejected hypotheses as compared to the gold standard. 
Comparing the calculated p-values for bias where an unbiased estimator would 
demonstrate a 50/50 split being greater than and less than the gold standard, DBI 
was closer to the gold standard with at 48.7/51.3 split, as compared to the 25.8/74.2 
split of MBI. cOnclusiOns: DBI was found to be more accurate and unbiased as 
compared to MBI methods. As a result, when studies are small and do not contain a 
large number of variables, or in situations where more elaborate imputation meth-
ods cannot be done, DBI is an accurate and unbiased method.
PRM69
inDiRect coMPARison of tHe effects of Anti-tnf biologicAl Agents 
in PAtients WitH AnKylosing sPonDylitis by MeAns of A MiXeD 
tReAtMent coMPARison PeRfoRMeD on efficAcy DAtA fRoM PublisHeD 
RAnDoMiseD, contRolleD tRiAls
Migliore A., Bizzi E., Massafra U.
S. Pietro Fatebenefratelli Hospital, Rome, Italy
Objectives: To compare ASAS (Assessment in Ankylosing Spondylitis Response 
Criteria) 20 response patterns between anti-TNF biological agents in patients with 
ankylosing spondylitis by means of a mixed treatment comparison of different ran-
domised, controlled trials (RCTs) on the efficacy of biological therapies. MethOds: 
A systematic review of literature was performed to identify a number of similarly 
designed double-blind, randomized, placebo-controlled trials investigating the effi-
cacy of the TNF-alfa inhibitors etanercept, infliximab, golimumab, certolizumab 
pegol and adalimumab in the treatment of ankylosing spondylitis patients, con-
ducted over an 18-years period. The endpoint of interest was ASAS20 response 
criteria at 12 weeks. Results were analyzed simultaneously using Bayesian mixed 
treatment comparison techniques. Results were expressed as odds ratio (OR) of 
ASAS20 response and associated 95% credible intervals (CrIs). The probability of 
being the best treatment was also reported. Results: 6 RCTs were selected for data 
extraction and further analysis. By mean of MTC, all anti-TNF agents demonstrated 
to be more efficacious in inducing a ASAS20 response than placebo. Infliximab 
shows a 67,6% of probability of being the best treatment of all. Adalimumab, goli-
mumab and etanercept show probabilities of 17,7%, 10,6% and 4%, respectively, 
while certolizumab pegol showed a probability of being the best treatment of 0,1%. 
No differences were observed when comparing directly an anti-TNFalfa agent 
against another. cOnclusiOns: Even if the mixed treatment comparisons between 
infliximab, golimumab, certolizumab pegol, adalimumab and etanercept did not 
show a statistically signiﬁcant difference, this analysis suggests that infliximab, 
compared to placebo, is expected to provide the highest rate of ASAS20 response 
in SA patients naive to biologic treatments.
PRM70
A tutoRiAl on DiMensionAlity ReDuction in lARge clAiMs DAtA sets
Juneau P.
Truven Health Analytics, Boyds, MD, USA
Objectives: The objective of this presentation will be to introduce the audience 
to various data dimension reduction techniques that may be applied in the setting 
of a large commercial claims data set to facilitate the task of identifying important 
factors or key features for use in subsequent analysis. MethOds: The author will 
provide a brief survey of the data dimension reduction literature from areas as 
diverse as image analysis, neural networks, gene expression microarrays, and high 
through-put chemistry to demonstrate that despite that many of these techniques 
have been used in other settings or areas of research, their application to the analy-
sis of health care claims data is relevant and potentially quite useful. Results: 
One, all-purpose, optimal data dimension technique does not exist for application 
in the analysis of health care claims data. The analyst needs to weigh the features 
of the large data set under consideration, the objectives of the downstream or sub-
sequent analysis, and the availability of tools for ease of use and interpretation 
of results. cOnclusiOns: The number of data dimension reduction techniques 
available to claims data set researchers is large and diverse; however, keys features 
of these various approaches can help the analyst make an informed decision that 
is effective with some simple setting and objectives diagnosis.
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half-cycle correction method provided more accurate results than calculations with-
out any kind of half-cycle correction with the exception of one set of input param-
eters. cOnclusiOns: Based on our model the most accurate method for half-cycle 
correction is Simpson’s method as in most cases it was the closest to real data. It is 
important to note that with a few exceptions even the standard method’s results were 
more accurate than in cases where no half-cycle correction was applied.
PRM77
APPlicAtion of A MoDel of Decision bAseD on fuzzy logic to 
PHARMAcoeconoMics: tReAtMent of cRoHn’s DiseAse WitH Antitnf in 
out of lAbel use
Alonso Herreros J.M.1, González-Cuello A.2
1HOSPITAL LOS ARCOS MAR MENOR, SAN JAVIER (MURCIA), Spain, 2Murcia University, 
MURCIA, Spain
Objectives: We present a model decision based on fuzzy logic, and apply to off 
label use of antiTNF in Crohn’s disease (CD) (Infliximab (IFB) 10 mg/kg/8 weeks, 
adalimumab (ADA) 80mg/2 weeks,. Certolizumab (CZB) 200mg/2weeks). The term 
“fuzzy logic” (FL) was introduced in 1965 by LAZadeh. Compared to traditional logic, 
FL variables may have a truth value in degree. FL has been applied to many fields, from 
economic analysis, to artificial intelligence. However it has not been applied so far to 
pharmacoeconomics. MethOds: According to a decision analysis model based on FL 
four fuzzy variables that affect the choice of treatment are defined: treatment success 
(expressed as a probability), cost of success, cost of failure (expressed as inverses), 
and other conditions about the cost (negotiation, handling of drugs...). Based on the 
value of these fuzzy variables, three linguistic variables (High, Medium, Low) are 
defined to expressing convenience of choice. The combination of the three possible 
values for each of the variables gives us 81 possible decision rules, so that the (HHHH) 
would be the most favorable option and (LLLL) the more unfavorable. So a new fuzzy 
variable called “ranking” is established for classifying these options with 7 possible 
values (Very-unfavorable, unfavorable, slightly-unfavorable, neutral, slightly-favorable, 
favorable, very-favorable). The value of the fuzzy variables for antiTNF at 52 weeks 
of treatment, were established based recent meta-analysis and reviews. Results: 
The matrices obtained and corresponding decision rules were: for IFB (0.65, 6.3 10-5, 
-1.17 10-4, 0.075) / (MMML); For ADA (0.41, 9.21 10-5, 6.4 10-5, 0.075) / (MMML); for CZB 
(0.52, 1.30 10-4 1.5 10-4 0.075) / (MHHB). Thus the CZB would be the “slightly-favorable” 
option, versus IFB and ADA (unfavorables). cOnclusiOns: It possible to apply meth-
ods of “FL” to pharmacoeconomic studies According to the model, Certolizumab would 
be a most favorable choice in off-label use for CD.
PRM78
Multi-cRiteRiA Decision AnAlysis (McDA): testing A PRoPoseD McDA 
MoDel foR oRPHAn DRugs
Schey C.1, Connolly M.2
1Unit of PharmacoEpidemiology & PharmacoEconomics, Groningen, The Netherlands,, 2University 
of Groningen, Groningen, The Netherlands
Objectives: Since the introduction of the orphan drugs in Europe, it has been sug-
gested that the general method of appraising drugs for reimbursement is not nec-
essarily suitable for orphan drugs. The National Institute for Health and Clinical 
Excellence indicated that several criteria other than cost and efficacy could be 
considered in reimbursement decisions for orphan drugs. The aim of this study 
was to apply a MCDA framework that was proposed by Hughes-Wilson et al (2012) 
to a range of orphan drugs in different diseases to test the correlation between 
drug price and aggregated MCDA scores for each product. MethOds: A MCDA 
framework was developed using the nine criteria suggested by Hughes-Wilson 
et al. A supplementary literature review was conducted to identify other attrib-
utes described in the application of MCDA in rare diseases. A numerical scoring 
system on a scale of one to three was developed for each criterion. Correlations 
between the average annual cost of the drugs and aggregate MCDA scores were 
tested and plotted graphically. Different weightings for each of the attributes were 
also tested. A further analysis was conducted to test the impact of including the 
drug cost as an attribute in the aggregate index scores. Results: The literature 
review identified further commonly cited criteria: ‘convenience of administra-
tion’, ‘age of the target population’, ‘quality of life’, and ‘drug innovation’ that 
were added to the aggregate index scores. In the drugs studied, the R2was 0.808 
and 0.704 when costs were included and not included, respectively. The standard 
error of the slope varied from 7711.9 to 11413.3 when costs were included and not 
included, respectively. cOnclusiOns: This quantitative study provided insight 
into using MCDA and its relationship to annual costs. Further work should explore 
the potential for therapy-specific MCDAs and how to inform value-based pricing 
assessment.
PRM79
ADvisHe: A neW tool to RePoRt vAliDAtion of HeAltH-econoMic 
Decision MoDels
Vemer P.1, Corro Ramos I.2, Van Voorn G.3, Al M.J.2, Feenstra T.L.4
1UMC Groningen, Groningen, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands, 
3Wageningen University & Research, Wageningen, The Netherlands, 4University of Groningen, 
University Medical Center Groningen, Groningen, The Netherlands
bAckgROund: Modelers and reimbursement decision makers could both profit 
from a more systematic reporting of the efforts to validate health-economic (HE) 
models. Objectives: Development of a tool to systematically report validation 
efforts of HE decision models and their outcomes. MethOds: A gross list of model 
validation techniques was collected using a literature review, including sources 
outside the HE field. A panel then selected the most important items. Based on 
the Delphi method, the panel members could score items in three e-mail rounds. 
Participants were HE modelling experts, covering various nationalities and work 
environments. They could comment on relevance, feasibility and formulation of 
the items and received feedback on comments from others. This resulted in a draft 
tool of selected items, which was tested and improved in two further rounds. In 
population are 18.5% for males and 9.8% for females. cOnclusiOns: Random sam-
pling from patient level data provided the best approximation of actual NHANES 
population predicted CVD rates. The cholesky decomposition approach was slightly 
limited since only continuous variables could be utilized which could explain the 
deviation from the population predicted CVD rates. Independent sampling under-
estimated the mean risk by ~20%, an interesting finding as many individual simula-
tion models created patients with this approach. Researchers should be cautious 
in their use of summary statistics when populating individual simulation models.
PRM74
vAliDAtion of tHe sPHR DiAbetes PRevention MoDel
Thomas C., Watson P., Squires H., Chilcott J., Brennan A.
University of Sheffield, Sheffield, UK
Objectives: We have developed a model to evaluate type-2 diabetes prevention 
interventions. We aimed to validate this model against external data to test the accu-
racy of model predictions. MethodsAn individual patient simulation was developed 
to predict longitudinal trajectories of HbA1c, 2-hr glucose, FPG, BMI, systolic blood 
pressure, total cholesterol and HDL cholesterol based on statistical analyses of the 
Whitehall II longitudinal cohort. Criteria for diabetes diagnosis were flexibly speci-
fied. Cardiovascular events were estimated from the QRISK2 algorithm. Microvascular 
complications of diabetes were estimated from the UKPDS outcomes model. Several 
validations were performed to compare model outcomes with reported data from 
external sources. We assessed the predicted diabetes incidence using data from the 
EPIC Norfolk cohort. Data from the Health Survey for England (HSE) 2003 cohort was 
simulated for eight years to compare predicted disease incidence and metabolic 
distributions with HSE 2011 data. We compared microvascular, cardiovascular and 
mortality outcomes in a diabetic population with those observed in the UKPDS. We 
assessed the performance of the model in predicting the results of the ADDITION trial 
for diabetes screening. Results: We found that the model overestimated three-year 
incidence of diabetes, particularly in high risk (HbA1c> 6.0) individuals, but underesti-
mated diabetes incidence in medium risk individuals (HbA1c 5.5-5.9) compared with 
the EPIC-Norfolk data. Predictions from HSE 2003 were fairly accurate. Predictions 
for microvascular events were similar to the UKPDS, but cardiovascular disease and 
mortality were slightly under-predicted. The model replicated the non-significant 
difference seen between control and intervention arms of the ADDITION trial, but 
overestimated total mortality and cardiovascular disease. cOnclusiOns: The SPHR 
Diabetes model appears to be fairly accurate at predicting external data, but has 
a tendency to overestimate mortality rates in a newly diagnosed diabetic cohort, 
and underestimate cardiovascular disease and mortality compared with the UKPDS.
PRM75
use of MoDel AveRAging tecHniques in cost-effectiveness AnAlysis 
in oncology
Le H.H., Ozer-Stillman I.
Evidera, Boston, MA, USA
Objectives: Often in cost-effectiveness analysis (CEA) of oncologic drugs, survival 
data from a randomized controlled trial are extrapolated to a lifetime horizon using 
parametric regression techniques. To capture parameter uncertainty in the analysis, 
regression parameters along with other model parameters are varied in probabilistic 
sensitivity analysis. However, structural uncertainty in the choice of regression 
model is rarely investigated. This study discusses the use of model averaging and 
provides an example to address structural uncertainty in CEA. MethOds: Using a 
cohort partition model, the numbers of patients in “progression-free”, “progressed”, 
and “dead” health states were calculated directly from progression-free survival 
(PFS) and overall survival (OS) curves. Weibull, exponential, lognormal, log-logistic, 
generalized gamma, and Gompertz parametric models were used to extrapolated 
these curves to a lifetime horizon. Total costs, life year (LY), and quality adjusted 
life year (QALY) for each regression model were estimated. Weighted results across 
all models were calculated, based on weights that were derived from Akaike’s or 
Bayesian Information Criterion (AIC or BIC) parameters. Results: Evaluating 
solely on BIC values, the lognormal distribution was identified as the best model 
for both survival curves. This resulted in the lowest observed ICERs. When model 
selection was based on considerations involving the log-cumulative hazard plots, 
clinical plausibility, and AIC/ BIC for each distribution, the Weibull distribution was 
selected for both curves, resulting in a 29% and 27% increase in the ICER for QALY 
and LY, respectively. Similar increases were observed when model averaging was 
applied using BIC-derived weights. In this case, model averaging produced results 
that were similar to those where model selection was based on multiple criteria.  
cOnclusiOns: Choice of parametric models often has the biggest impact on the 
outcomes in CEAs in oncology. Model averaging takes into account the structural 
uncertainty surrounding the choice of parametric models.
PRM76
coMPARing tHRee DiffeRent MetHoDs of HAlf-cycle coRRection
Nemeth B., Szeker V.
National Institute of Quality- and Organizational Development in Healthcare and Medicines, 
Budapest, Hungary
Objectives: To compare three different half-cycle correction methods and their 
effect on the final results of Markov models. MethOds: To assess the relative per-
formance of the alternatives to the standard half-cycle correction we constructed a 
5-state Markov model where the courses of the number of patients in health states 
follow different shapes to represent the most likely cases in modelling practise. We 
applied three different correction methods (standard half-cycle correction, Simpson’s 
method and using the mid-cycle values) and we also looked at the results without any 
correction and with different numbers of Markov cycles. We conducted a sensitivity 
analysis by changing the input parameters of our model. In total we examined 80 
cases. Results: In our Markov model Simpson’s method provided the most accurate 
results where the difference from real data was less than 0.1% in 67 of the 80 cases. 
The second most accurate method was using the mid-cycle values. The standard 
